Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CLaret Embolic Protection ANd TAVI - Trial (CLEAN-TAVI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01833052
Recruitment Status : Unknown
Verified May 2015 by Prof. Dr. med. A. Linke, University of Leipzig.
Recruitment status was:  Active, not recruiting
First Posted : April 16, 2013
Last Update Posted : May 5, 2015
Sponsor:
Information provided by (Responsible Party):
Prof. Dr. med. A. Linke, University of Leipzig

Brief Summary:
This prospective, randomized study was designed to investigate the benefit of using a Filter-Protection-Device (Claret MontageTM Dual Filter System) during transcatheter aortic valve implantation (TAVI) with a Medtronic CoreValve®.

Condition or disease Intervention/treatment Phase
Frequency of Cerebral Perfusion Defects After TAVI Size of Cerebral Perfusion Defects After TAVI Device: TAVI (Medtronic CoreValve) Device: Claret-Filter Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Supportive Care
Study Start Date : April 2013
Actual Primary Completion Date : June 2014
Estimated Study Completion Date : June 2015

Arm Intervention/treatment
Cerebral Protection Filter
Patient is treated with Cerebral protection Filter.
Device: TAVI (Medtronic CoreValve)
Device: Claret-Filter
No Cerebral Protection Filter
Patient is not treated with Cerebral protection Filter.
Device: TAVI (Medtronic CoreValve)



Primary Outcome Measures :
  1. Rate and Size of Cerebral Embolism [ Time Frame: 2 days after Intervention ]
    Primary endpoint ist the rate and the size of cerebral embolism in postinterventional Magnetic Resonance Imaging (MRI).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must be scheduled to undergo an endovascular aortic valve prosthesis (Medtronic CoreValve®) implant procedure with the femoral artery as the intended access site for the valve delivery system.

Exclusion Criteria:

  • Patient is unsuitable for TAVI
  • Prior Stroke or TIA in the last 12 month
  • Carotic stenosis >70%
  • Relevant stenosis of the brachiocephalic trunc or the right subclavian artery
  • Expected Non-compliance for follow-ups
  • Pregnancy
  • Patient is already recruited for another study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01833052


Locations
Layout table for location information
Germany
Leipzig Herzzentrum
Leipzig, Germany, 04289
Sponsors and Collaborators
University of Leipzig

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Prof. Dr. med. A. Linke, University of Leipzig
ClinicalTrials.gov Identifier: NCT01833052     History of Changes
Other Study ID Numbers: HZL-01-TAVI
First Posted: April 16, 2013    Key Record Dates
Last Update Posted: May 5, 2015
Last Verified: May 2015